US Stock MarketDetailed Quotes
POAI Predictive Oncology
- 0.6866
- -0.0535-7.23%
Close Nov 15 16:00 ET
- 0.6866
- 0.00000.00%
Post 20:01 ET
4.58MMarket Cap-234P/E (TTM)
0.7825High0.6500Low145.78KVolume0.7400Open0.7401Pre Close100.21KTurnover2.28%Turnover RatioLossP/E (Static)6.67MShares3.760052wk High2.33P/B4.40MFloat Cap0.550052wk Low--Dividend TTM6.41MShs Float1910.0000Historical High--Div YieldTTM17.90%Amplitude0.5500Historical Low0.6870Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Predictive Oncology Stock Forum
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Q3 2024 and Recent Highlights:
• Announced the results of an additional study that successfully demonstrated the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples stored within the Company's proprietary biobank.
◦ The samples stored in the biobank had originally been tested and cryopreserved between 2008 and 2016.
◦ The ...
The integration of artificial intelligence and biobanking has emerged as a formidable force, enabling researchers to harness vast volumes of data in the quest to develop novel therapies. At the forefront of this revolution is Predictive Oncology Inc. (NASDAQ: POAI), a company that has recently anno...
Predictive Oncology Announces Results Of Study Showing Long-Term Stability And Viability Of Over 150K Cryopreserved Patient Tumor Samples At Its Biobank
Predictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development
Predictive Oncology Inc. (NASDAQ: POAI) has expanded applications for its AI-driven drug discovery platform to address patient heterogeneity and improve drug development success rates. The company's approach integrates artificial intelligence, machine learning, and a biobank of cryopreserved patient-derived tumor samples to i...
I hope this counter will come back against..
No comment yet